As part of post-marketing clinical monitoring and with a view to applying for the digital medical device Quitoxil® to be included on the LPPR list, this prospective, multicentre, controlled, randomised clinical trial aims to evaluate the clinical impact of support provided by Quitoxil® as an adjunct to conventional management for patients undergoing smoking cessation who have a tobacco use disorder.
Inclusion Criteria:
Exclusion Criteria:
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy
Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking
Innovative Digital Therapeutic for Smoking Cessation
Personalized Dosing of Nicotine Replacement (NRT to Effect)
A Comparative Effectiveness RCT of Optimized Cessation Treatments
Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation